Articles

A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma

Department of Hematology and Hematopoietic Cell Transplant, City of Hope, Duarte, CA, USA
Department of Biostatistics, City of Hope, Duarte, CA, USA
Department of Hematology and Hematopoietic Cell Transplant, City of Hope, Duarte, CA, USA
Department of Hematology and Hematopoietic Cell Transplant, City of Hope, Duarte, CA, USA
Department of Biostatistics, City of Hope, Duarte, CA, USA
Department of Radiology, City of Hope, Duarte, CA, USA
Department of Hematology and Hematopoietic Cell Transplant, City of Hope, Duarte, CA, USA
Department of Hematology and Hematopoietic Cell Transplant, City of Hope, Duarte, CA, USA
Department of Hematology and Hematopoietic Cell Transplant, City of Hope, Duarte, CA, USA
Department of Hematology and Hematopoietic Cell Transplant, City of Hope, Duarte, CA, USA
Department of Hematology and Hematopoietic Cell Transplant, City of Hope, Duarte, CA, USA
Department of Hematology and Hematopoietic Cell Transplant, City of Hope, Duarte, CA, USA
Department of Hematology and Hematopoietic Cell Transplant, City of Hope, Duarte, CA, USA
Vol. 100 No. 3 (2015): March, 2015 https://doi.org/10.3324/haematol.2014.117473